Filing Details
- Accession Number:
- 0000899243-23-006981
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-03 16:30:52
- Reporting Period:
- 2023-03-01
- Accepted Time:
- 2023-03-03 16:30:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1815442 | Kymera Therapeutics Inc. | KYMR | Biological Products, (No Disgnostic Substances) (2836) | 812992166 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821198 | Jared Gollob | C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-03-01 | 18,750 | $0.00 | 76,007 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-03-02 | 1,001 | $30.88 | 75,006 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-03-02 | 297 | $31.40 | 74,709 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2023-03-01 | 112,500 | $0.00 | 112,500 | $32.07 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 112,500 | 2033-02-28 | No | 4 | A | Direct |
Footnotes
- Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
- Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.
Billionaire Hedge Funds
